Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + surufatinib + toripalimab
- Development stage
- Preclinical
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of pemetrexed (a folate analog chemotherapy agent), surufatinib (an angio-immuno kinase inhibitor targeting VEGFRs 1, 2, and 3, fibroblast growth factor receptor 1, and colony stimulating factor 1 receptor), and toripalimab (a PD-1 inhibitor). The combination has been studied for the treatment of non-small cell lung cancer (NSCLC).
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)GART (GAR transformylase)DHFR (Dihydrofolate reductase)CSF1R (Macrophage colony-stimulating factor receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + surufatinib + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + surufatinib + toripalimab.